Journal
BLOOD CANCER JOURNAL
Volume 11, Issue 6, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41408-021-00503-6
Keywords
-
Categories
Ask authors/readers for more resources
Core binding factor acute myelogenous leukemia (CBF-AML) is considered good-risk AML and can be improved through effective therapeutic measures and disease monitoring. Incorporation of gemtuzumab ozogamicin and monitoring of residual disease can lead to better prognosis and treatment modifications.
Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective implementation of available therapeutic measures and appropriate disease monitoring. The incorporation of gemtuzumab ozogamicin into frontline therapy should be standard. Cytarabine based induction/consolidation regimen may be combined with anthracycline (3 + 7 standard) or antimetabolite, fludarabine. Serial quantitative polymerase chain reaction (QPCR) monitoring of unique fusion transcripts allows monitoring for measurable residual disease clearance; this allows for better prognostication and well as treatment modifications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available